Using liquid biopsy for diagnosing and monitoring immune-related lymphoproliferative disorders
Liquid Biopsy-based Genomic Assay to Enable Non-invasive Precision Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders (ILD)
This study is testing a new way to use blood samples to help diagnose and track the progress of immune-related lymphoproliferative disorders in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Drugs / interventions | Rituximab |
| Locations | 6 sites (Basel and 5 other locations) |
| Trial ID | NCT05803616 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect clinical data and biological samples from patients diagnosed with immune-mediated lymphoproliferative disorders (ILD). It will utilize liquid biopsy techniques to analyze circulating tumor DNA (ctDNA) at various clinical points, including diagnosis and treatment follow-ups. The study will also incorporate imaging data through a web-based platform for independent review of disease staging and response. By gathering this information, the study seeks to improve the understanding and management of ILD, particularly in cases where traditional monitoring methods are ineffective.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with immune-mediated lymphoproliferative disorders as defined by WHO HAEM 5, including those in post-transplant settings.
Not a fit: Patients with non-immune-mediated lymphoproliferative disorders or those with concurrent HIV infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnosis and monitoring of immune-mediated lymphoproliferative disorders, improving patient outcomes.
How similar studies have performed: While the use of liquid biopsy is a growing area of interest, this specific application for immune-mediated lymphoproliferative disorders is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient with a diagnosis of ILD defined by the World Health Organization (WHO HAEM 5)(e.g. post-transplant setting, X-link, concomitant auto-immune disorders) Exclusion Criteria: * Lymphoproliferative disorders non immune-mediated * Lymphoproliferative disorders occurring in the context of a concomitant human immunodeficiency virus (HIV) infection
Where this trial is running
Basel and 5 other locations
- Basel University Hospital — Basel, Switzerland (Not_yet_recruiting)
- Oncology Institute of Southern Switzerland — Bellinzona, Switzerland (Not_yet_recruiting)
- Inselspital — Bern, Switzerland (Recruiting)
- Hôpitaux Universitaires de Genève (HUG) — Geneva, Switzerland (Recruiting)
- Kantonsspital — St Gallen, Switzerland (Not_yet_recruiting)
- University Hospital Zürich — Zürich, Switzerland (Not_yet_recruiting)
Study contacts
- Principal investigator: Noemie Lang, MD — Geneva Univresity Hospital
- Study coordinator: Noemie Lang, MD
- Email: noemie.lang@hcuge.ch
- Phone: +41795532406
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.